Our perspectives
in one place
Topic
Selected filters
Clear
News
See allStatement delivered at the 13th Intergovernmental Negotiating Body (INB 13)
On 17 February 2025, IFPMA delivered a statement during the 13th Intergovernmental Negotiating Body (INB 13).
Read more156th WHO Executive Board (EB156): Constituency statement on climate change and health
On 8 February 2025 at the EB156 in Geneva, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA), Global Self-Care Federation (GSCF), and International Hospital Federation (IHF) delivered a statement on Agenda Item 22: Climate change and health.
Read more156th WHO Executive Board (EB156): Fight the Fakes Alliance statement on substandard and falsified products
On 7 February 2025 at the EB156 in Geneva, the Fight the Fakes Alliance delivered a statement on substandard and falsified medical products. IFPMA is a member of Fight the Fakes Alliance.
Read more156th WHO Executive Board (EB156): Constituency statement on health emergencies
On 6 February at the EB156, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA), Global Self-Care Federation (GSCF), International Pharmaceutical Federation (FIP), International Alliance of Patients’ Organizations (IAPO), and International Generic and Biosimilar Medicines Association (IGBA) delivered a statement on Agenda Item 15: WHO’s work in health emergencies.
Read more156th WHO Executive Board (EB156): Individual statement on non-communicable diseases
On 5 February at the EB156 in Geneva, IFPMA delivered a statement on non-communicable diseases (NCDs).
Read moreStatement on the revision of the Declaration of Helsinki on ethical principles for medical research
On 19 October 2024, the World Medical Association (WMA) General Assembly unanimously voted to adopt a set of revisions to the Declaration of Helsinki on ethical principles for medical research.
Read morePublications
See allPharmacy-mediated substitution for biosimilars
Pharmacy-mediated substitution is a framework permitting substitution of medicines at the retail pharmacy without the consent of the prescribing physician. In this paper, IFPMA outlines a set of principles that can guide pharmacy-mediated substitution. While the principles are intended for the awareness of pharmacists, they can also relate to other healthcare providers, regulators, payers, and those involved in formulary and procurement decision-making.
Read more
Global regulatory approaches to post-approval changes in biotherapeutic products
IFPMA worked with Clarivate to study how different countries regulate post-approval changes (PACs) in biotherapeutic products. The research compared PACs guidelines across 21 countries and regions in Latin America (LATAM), Asia-Pacific (APAC), and the Middle East and Africa (MEA) to the World Health Organization (WHO) Guidelines on changes on biotherapeutic products. The findings reveal significant diversity in the level of convergence among countries and with the WHO Reference Guidelines, with a few notable trends.
Read more
#AlwaysInnovating: Pharmaceutical Industry Facts & Figures
This compendium of facts and figures aims to provide a snapshot of the contribution of the pharmaceutical industry. Pharmaceutical companies are at the forefront of developing medicines and vaccines that change how we fight and prevent disease and help solve today’s biggest health challenges. In addition to their contribution to healthier societies, pharmaceutical companies also...
Read more
Expert insights
See all
Adaptive HTA: striking the right balance between rapid assessments and local health impact
Read more
Unlocking the full value of life-course immunization: A key to sustainable healthcare
Read more
How lifelong vaccination can tackle the challenges of an ageing world
Read moreResources
See allOur Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more
Action on NCDs: How the innovative pharmaceutical industry helps bridge the care gap
Read more